Bifidobacterium animalis ssp. Lactis 420 Mitigates Autoimmune Hepatitis Through Regulating Intestinal Barrier and Liver Immune Cells

Hongxia Zhang,Man Liu,Xin Liu,Weilong Zhong,Yanni Li,Ying Ran,Liping Guo,Xu Chen,Jingwen Zhao,Bangmao Wang,Lu Zhou
DOI: https://doi.org/10.3389/fimmu.2020.569104
IF: 7.3
2020-10-06
Frontiers in Immunology
Abstract:Autoimmune hepatitis (AIH) is an immune-mediated inflammatory liver disease of uncertain cause. Accumulating evidence shows that gut microbiota and intestinal barrier play significant roles in AIH thus the gut-liver axis has important clinical significance as a potential therapeutic target. In the present study, we found that <i>Bifidobacterium animalis</i> ssp. lactis 420 (B420) significantly alleviated S100-induced experimental autoimmune hepatitis (EAH) and modulated the gut microbiota composition. While the analysis of clinical specimens revealed that the fecal SCFA quantities were decreased in AIH patients, and B420 increased the cecal SCFA quantities in EAH mice. Remarkably, B420 application improved intestinal barrier function through upregulation of tight junction proteins in both vitro and vivo experiments. Moreover, B420 decreased the serum endotoxin level and suppressed the RIP3 signaling pathway of liver macrophages in EAH mice thus regulated the proliferation of Th17 cells. Nevertheless, the inhibition effect of B420 on RIP3 signaling pathway was blunted <i>in vitro</i> studies. Together, our results showed that early intervention with B420 contributed to improve the liver immune homeostasis and liver injury in EAH mice, which might be partly due to the protection of intestinal barrier. Our study suggested the potential efficacy of probiotics application against AIH and the promising therapeutic strategies targeting gut-liver axis for AIH.
immunology
What problem does this paper attempt to address?
The paper primarily explores the role of Bifidobacterium animalis subsp. lactis B420 (B420) in the treatment of autoimmune hepatitis (AIH) and the mechanisms by which it achieves this effect through the regulation of the gut barrier and liver immune cells. Specifically, the study found that B420 significantly alleviated S100-induced experimental autoimmune hepatitis (EAH) and modulated the composition of the gut microbiota. Analysis of clinical samples revealed that the fecal short-chain fatty acid (SCFA) content was reduced in AIH patients, while B420 increased the SCFA content in the cecum of EAH mice. Notably, B420 improved gut barrier function by upregulating the expression of tight junction proteins and reduced serum endotoxin levels. It also inhibited the RIP3 signaling pathway in liver macrophages of EAH mice, thereby regulating the proliferation of Th17 cells. In summary, early intervention with B420 helps improve liver immune homeostasis and liver injury in EAH mice, which may be partly attributed to its protective effect on the gut barrier. This study suggests that the application of probiotics has potential therapeutic efficacy for AIH and indicates that targeting the gut-liver axis may be a promising therapeutic strategy for AIH.